Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289962 · ClinicalTrials.gov registry record · Phase 1
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 273
- Enrollment target
NCT03289962: Completed Phase 1 study, sponsored by Genentech.
NCT03289962 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 273 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (355% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289962, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 273 participants
- Enrollment target
Study Summary
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).
Interventions
- DRUG Atezolizumab
- DRUG Autogene cevumeran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
What the finished NCT03289962 record still lists
NCT03289962 is an interventional study that assigns participants to a tested intervention. The registered 273 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (355% higher).
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03289962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03289962 about?
NCT03289962 is a clinical study titled "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors". This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-...
What is the current status of trial NCT03289962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 273 participants. The study started on 2017-12-21. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT03289962?
The interventions under investigation include: Atezolizumab (DRUG), Autogene cevumeran (DRUG).
Who is sponsoring clinical trial NCT03289962?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03289962's enrollment target sits among peer trials
273 149th of 2000 higher than 1,852 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07229430 · 273 participants · NA
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI